Regístrate
Data from contemporary registry confirms that four out of five patients with heart failure with reduced ejection fraction eligible for treatment with FARXIGA
Data from contemporary registry confirms that four out of five patients with heart failure with reduced ejection fraction eligible for treatment with FARXIGA
Noviembre 19, 2020

TRANSLATE-HF study establishes the potential for broad use of the only SGLT2 inhibitor indicated in patients with heart failure with reduced ejection fraction with and without diabetes.